| Literature DB >> 30127905 |
Qingyun Duan1, Mei Xu2, Xiong Zhang1, Muyun Jia3, Rongtao Yuan3, Min Gan1.
Abstract
The present study aims to analyze the expression of broad spectrum cytokeratin in the cervical lymph nodes of patients with mandibular gingival squamous cell carcinoma and explore the metastasis of mandibular gingival squamous cell carcinoma in cervical lymph nodes. This study included 42 patients with mandibular gingival squamous cell carcinoma, which was staged according to the clinical staging criteria by International Union Against Cancer 2002 (UICC) and the Level staging method of cervical lymph node by American Academy of Otolaryngology-Head and Neck Surgery 1991. Monoclonal mouse anti-human cytokeratin (AE1/AE3) antibody was used in immunohistochemical examination and hematoxylin and eosin (H&E) staining. All positive sections by H&E staining were also positive by immunohistochemistry (IHC). The positive rate of routine H&E staining and serial-section H&E staining was 8.03 and 9.57%, respectively, the positive rate of IHC was 12.82%. The positive rate of IHC was significantly different with that of routine H&E staining (χ2=7.17, P<0.01), yet not significantly different with that of serial-section H&E staining (χ2=3.10, P>0.05). Lymph node metastasis was mainly in Level I, II and III, both serial-section H&E staining and IHC showed lymph node metastasis in Level IV for advanced patients. IHC showed 19 lymph node micrometastasis in 12 patients, while neither serial-section nor routine H&E staining showed micrometastasis. Lymph node dissection of hyoid bone (mainly in Level I, II and III) could be used for early patients, and the dissection could be expanded to Level IV for advanced patients.Entities:
Keywords: cytokeratin; immunohistochemistry; lymph node metastasis; mandibular gingival squamous cell carcinoma
Year: 2018 PMID: 30127905 PMCID: PMC6096087 DOI: 10.3892/ol.2018.9005
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
The distribution and metastasis of mandibular gingival squamous cell carcinoma in cervical lymph nodes by routine pathological examination.
| Distribution in cervical lymph node | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Level I | Level II | Level III | Level IV | Level V | ||||||
| Stage/No. | P | N | P | N | P | N | P | N | P | N |
| T1/9 | 1 | 20 | 1 | 19 | 1 | 17 | 0 | 14 | 0 | 12 |
| T2/16 | 5 | 46 | 2 | 48 | 1 | 50 | 0 | 38 | 0 | 18 |
| T3/6 | 4 | 34 | 6 | 18 | 2 | 20 | 0 | 24 | 0 | 5 |
| T4/11 | 12 | 43 | 7 | 28 | 5 | 32 | 0 | 35 | 0 | 17 |
| In total | 22 | 143 | 16 | 113 | 9 | 119 | 0 | 111 | 0 | 52 |
| Metastatic rate (%) | 13.33 | 12.4 | 7.03 | 0 | 0 | |||||
N, negative; P, positive.
The distribution and metastasis in cervical lymph nodes by routine H&E staining, serial-section H&E staining and IHC.
| Routine H&E staining | Serial-section H&E staining | IHC | |||||
|---|---|---|---|---|---|---|---|
| Levels | No. | Positive | (%) | Positive | (%) | Positive | (%) |
| I | 165 | 22 | 13.33 | 22+2 | 14.54 | 22+9 | 18.78 |
| II | 129 | 16 | 12.4 | 16+3 | 14.72 | 16+7 | 17.82 |
| III | 128 | 9 | 7.03 | 9+3 | 9.37 | 9+8 | 13.28 |
| IV | 111 | 0 | 0 | +1 | 0.90 | +4 | 3.60 |
| V | 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 585 | 47 | 8.03 | 47+9 | 9.57 | 47+28 | 12.82 |
IHC, immunohistochemistry; H&E, hematoxylin and eosin.
Figure 1.Representative of lymph node micrometastasis by IHC. (A) Patchy lymph node metastasis (AE1/AE3 positive) (magnification, ×40). (B) Nest-like lymph node micrometastasis and subcapsular micrometastasis (2 mm) (magnification, ×40). (C) Disseminated nest-like lymph node micrometastasis (AE1/AE3 positive). IHC, immunohistochemistry.
The metastasis in cervical lymph nodes by routine H&E staining, serial-section H&E staining and IHC.
| Routine H&E staining | Serial-section H&E staining | IHC | |||||
|---|---|---|---|---|---|---|---|
| Staging | No. | Metastasis | (%) | Metastasis | (%) | Metastasis | (%) |
| T1 | 9 | 2 | 22.22 | 2 | 22.22 | 2+1 | 33.33 |
| T2 | 16 | 5 | 31.25 | 5+1 | 37.5 | 5+2 | 43.75 |
| T3 | 6 | 3 | 50 | 3 | 50 | 3+1 | 66.66 |
| T4 | 11 | 5 | 45.45 | 5+1 | 54.54 | 5+3 | 72.72 |
| Total | 42 | 15 | 35.71 | 15+2 | 40.47 | 15+7 | 52.38 |
IHC, immunohistochemistry.